HOW TRANSPARENT IS NH? FOLLOW OUR SCORECARD

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Geron Corporation - Common Stock (NQ:GERN)

0.9504 -0.1296 (-12.00%)
Delayed Quote Updated: 3:47 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Geron Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
Geron: 3 Key Takeaways for Long-Term Investors ↗
Operating expenses fell 9% year to date, and $339 million in cash leaves Geron room to pursue hematology deals. 
Via The Motley Fool
Topics Earnings
News headline image
Geron Corp (GERN) Q3 2026 Earnings Call Transcript ↗
First profit as a commercial-stage biotech, on RYTELO growth and cost cuts. 
Via The Motley Fool
Topics Earnings
News headline image
Geron Q3 Earnings Call Highlights ↗
Geron (NASDAQ:GERN) reported third-quarter net product revenue of $60.1 million for RYTELO, a 27% increase from $47.2 million a year earlier, as the company cited continued growth in prescribing,... 
Via MarketBeat
Topics Earnings
Geron (NASDAQ:GERN) Falls After Mixed Q2 Results; Revenue Beats but Loss Wider Than Expected ↗
Via Chartmill
Geron Corp. (NASDAQ:GERN) Beats Q1 Estimates as RYTELO Sales Momentum Continues ↗
Via Chartmill
Geron Corp (NASDAQ:GERN) Stock Plummets 10% After Q4 Revenue Miss ↗
Via Chartmill
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
Geron Earnings Preview ↗
 
Via Benzinga
Most Active Stocks in the 2026-10-28 US Session ↗
Via Chartmill
News headline image
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:BIOA),(NASDAQ:GERN),(NASDAQ:DNLI) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands ↗
Geron (NASDAQ:GERN) executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company... 
Via MarketBeat
News headline image
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands ↗
Geron (NASDAQ:GERN) said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company... 
Via MarketBeat
News headline image
Geron (GERN) Q2 2026 Earnings Call Transcript ↗
RYTELO demand grew 5% as prescribing accounts hit 1,575 since launch. 
Via The Motley Fool
Topics Earnings
News headline image
Geron Q2 Earnings Call Highlights ↗
Geron (NASDAQ:GERN) reported second-quarter net revenue of $57.5 million, up 17% from a year earlier and 11% sequentially, as the company continued to expand use of RYTELO among patients with... 
Via MarketBeat
Topics Earnings
News headline image
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Geron (GERN) Q1 2026 Earnings Call Transcript ↗
Geron (GERN) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Economy
News headline image
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Here are the top movers in Wednesday's session. ↗
Via Chartmill
News headline image
Geron (GERN) Q4 2025 Earnings Call Transcript ↗
Geron (GERN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Which stocks are moving before the opening bell on Wednesday? ↗
Via Chartmill
News headline image
Why Did GERN Stock Tumble 10% Pre-Market Today? ↗
Total revenue reached $48 million for the fourth-quarter with a loss per share (EPS) of $0.05, with both metrics coming in below street estimates. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Geron Corp (NASDAQ:GERN) Reports Mixed Q3 2025 Results, Misses Revenue Estimates ↗
Geron's Q3 2025 results show mixed performance, with RYTELO revenue up 67% year-over-year but missing analyst sales estimates, causing a negative market reaction. 
Via Chartmill
News headline image
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Geron Corporation
Via Business Wire
News headline image
Geron Corporation to Present at Upcoming Investor Conferences
From Geron Corporation
Via Business Wire
News headline image
Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies
From Geron Corporation
Via Business Wire
News headline image
Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025
From Geron Corporation
Via Business Wire
News headline image
GERON (GERN) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article